These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22084448)

  • 61. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The relationship between symptomatic and functional changes of Korean children and adolescents with attention-deficit/hyperactivity disorder treated with osmotic-controlled release oral delivery system-methylphenidate.
    Kim E; Cheon KA; Joung YS; Kim JY; Song DH
    Clin Neuropharmacol; 2015; 38(1):30-5. PubMed ID: 25580917
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task.
    Bush G; Spencer TJ; Holmes J; Shin LM; Valera EM; Seidman LJ; Makris N; Surman C; Aleardi M; Mick E; Biederman J
    Arch Gen Psychiatry; 2008 Jan; 65(1):102-14. PubMed ID: 18180434
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.
    Erder MH; Signorovitch JE; Setyawan J; Yang H; Parikh K; Betts KA; Xie J; Hodgkins P; Wu EQ
    J Med Econ; 2012; 15(6):1078-87. PubMed ID: 22537226
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.
    Winhusen TM; Somoza EC; Brigham GS; Liu DS; Green CA; Covey LS; Croghan IT; Adler LA; Weiss RD; Leimberger JD; Lewis DF; Dorer EM
    J Clin Psychiatry; 2010 Dec; 71(12):1680-8. PubMed ID: 20492837
    [TBL] [Abstract][Full Text] [Related]  

  • 66. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
    Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
    Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder.
    Tzang RF; Wang YC; Yeh CB; Hsu CD; Liang HY; Yang PC; Liu HJ; Huang YS; Cheng H; Hsu YC; Liu SI; Pan CH; Huang YF; Huang CF; Wu YY; Huang YH; Liu HC; Chang HL
    Psychiatry Clin Neurosci; 2012 Feb; 66(1):53-63. PubMed ID: 22250610
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.
    McGough JJ; Wigal SB; Abikoff H; Turnbow JM; Posner K; Moon E
    J Atten Disord; 2006 Feb; 9(3):476-85. PubMed ID: 16481664
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.
    Biederman J; Boellner SW; Childress A; Lopez FA; Krishnan S; Zhang Y
    Biol Psychiatry; 2007 Nov; 62(9):970-6. PubMed ID: 17631866
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation.
    Stevens JR; George RA; Fusillo S; Stern TA; Wilens TE
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):49-54. PubMed ID: 20166796
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day.
    Brams M; Moon E; Pucci M; López FA
    Curr Med Res Opin; 2010 Aug; 26(8):1809-25. PubMed ID: 20491612
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.
    Katzman MA; Sternat T
    CNS Drugs; 2014 Nov; 28(11):1005-33. PubMed ID: 25120227
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study.
    Remschmidt H; Hoare P; Ettrich C; Rothenberger A; Santosh P; Schmidt M; Spender Q; Tamhne R; Thompson M; Tinline C; Trott GE; Medori R
    Eur Child Adolesc Psychiatry; 2005 Sep; 14(6):297-304. PubMed ID: 16220213
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
    Yang L; Cao Q; Shuai L; Li H; Chan RC; Wang Y
    Int J Neuropsychopharmacol; 2012 Feb; 15(1):15-26. PubMed ID: 22017969
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder.
    Wilens TE; Boellner SW; López FA; Turnbow JM; Wigal SB; Childress AC; Abikoff HB; Manos MJ
    J Am Acad Child Adolesc Psychiatry; 2008 Jun; 47(6):700-708. PubMed ID: 18434918
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.
    Childress AC; Brams M; Cutler AJ; Kollins SH; Northcutt J; Padilla A; Turnbow JM
    J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):402-14. PubMed ID: 25692608
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Plasma Methylphenidate Levels in Youths With Attention Deficit Hyperactivity Disorder Treated With OROS Formulation.
    Yorbik O; Mutlu C; Ozilhan S; Eryilmaz G; Isiten N; Alparslan S; Saglam E
    Ther Drug Monit; 2015 Jun; 37(3):347-52. PubMed ID: 25384118
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.
    Swanson J; Gupta S; Lam A; Shoulson I; Lerner M; Modi N; Lindemulder E; Wigal S
    Arch Gen Psychiatry; 2003 Feb; 60(2):204-11. PubMed ID: 12578439
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A multicenter, open-label trial to evaluate the quality of life in adults with ADHD treated with long-acting methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) study.
    Mattos P; Louzã MR; Palmini AL; de Oliveira IR; Rocha FL
    J Atten Disord; 2013 Jul; 17(5):444-8. PubMed ID: 22334621
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
    Chronis-Tuscano A; Seymour KE; Stein MA; Jones HA; Jiles CD; Rooney ME; Conlon CJ; Efron LA; Wagner SA; Pian J; Robb AS
    J Clin Psychiatry; 2008 Dec; 69(12):1938-47. PubMed ID: 19192455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.